Aug 2026· Stem Cell Reports· Vol 21, pp. 103051· 0 citations· 78 references
Medicine
TL;DR
This work proposes a ten-metric benchmarking framework and discusses the opportunities and remaining challenges for translational readiness in tauopathy modeling, and identifies three challenges for their translational readiness, maturity, disease-relevant cellular complexity, and pathological accuracy.
Abstract
Summary A major hurdle in Alzheimer disease research is the failure of mouse models to capture complexities of the human brain that contributes to repeated clinical trial failure. Although the recent US Food and Drug Administration (FDA) Modernization Act 2.0 has enabled non-animal preclinical pathways, brain organoid models of tauopathies remain nascent compared with other disease areas. Here, we identify three challenges for their translational readiness, maturity, disease-relevant cellular complexity, and pathological accuracy, and examine current achievements and emerging solutions. We propose a ten-metric benchmarking framework and discuss the opportunities and remaining challenges for translational readiness in tauopathy modeling.
Alzheimer’s disease (AD) remains a major unmet medical challenge, highlighting the need for improved experimental models. The second Unconventional Animal Models of Alzheimer’s Disease and Aging (UAMAA 2026) conference brought together ~150 interdisciplinary researchers to discuss advances across 19 animal models of AD...
B. M. Garduño, T. Melgarejo, Patricia Cogram et al.· Lab animal· 0 citations
Neurodegenexrative diseases such as Alzheimer's disease and Parkinson's disease are diagnosed most reliably only after substantial, often irreversible, neuronal loss has already occurred, creating an urgent need for quantitative tools that can detect subtle, early, and individual-specific brain changes from neuroimagin...
Vishal Subedi, Shashipraba N. K. Rajakaruna, Pratyusha Sarkar et al.· 0 citations
Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which effective therapeutic interventions remain scarce, highlighting the urgent need for new molecular approaches. Small nucleolar RNAs (snoRNAs), classically known for directing ribosomal modifications, have recently emerged as multifunctional r...
Tripti Sharma, Prince Sharma, Bushra Bashir et al.· Drug Discovery Today· 0 citations
While amyloid-β (Aβ) has historically dominated the research landscape of Alzheimer’s disease (AD), the limited clinical success of Aβ-centric therapies has redirected focus toward tau pathology, which correlates more robustly with cognitive deterioration and synaptic dysfunction. Transcending the traditional linear...
Xue Li, Lei-Han Zhang, Li-Jun Zhao et al.· Journal of Translational Med...· 0 citations
Alzheimer’s and related dementias are not inevitable consequences of aging. This manuscript proposes that they arise when cumulative stress exceeds the repair capacity of three biological systems critical for maintaining brain health: proteostatic capacity, mitochondrial function, and neuroimmune regulation. In most ca...
Caroline C. Rodgers· Journal of Dementia and Alzh...· 0 citations
Pathological tau accumulation underlies a spectrum of neurodegenerative diseases collectively known as tauopathies. Although reducing tau remains the prevailing therapeutic strategy, indiscriminate tau reduction may compromise physiological functions and has demonstrated limited clinical efficacy. Growing evidence indi...
Hanyuan Zheng, Jie Zheng· TIPS - Trends in Pharmacolog...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
